Actinomycin D-Activated RNase L Promotes H2A.X/H2B-Mediated DNA Damage and Apoptosis in Lung Cancer Cells

Conclusion: This study unveiled the regulatory function and related mechanism of RNase L and implied the promising application of therapeutics targeting RNase L in lung cancer.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

In conclusion, the present study revealed that CtBP2 protein is a novel prognostic marker for LUAD. A further large-scale study is needed to confirm the present results.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
In this study, we examined the role of PKCe, an oncogenic kinase highly expressed in NSCLC and other cancers, in KRAS-driven tumorigenesis. Notably, database analysis revealed an association between PKCe expression and poor outcome in lung adenocarcinoma patients specifically having KRAS mutation. By generating a PKCe-deficient, conditionally activatable allele of oncogenic Kras (LSL-Kras G12D ;PKCe -/- mice) we were able to demonstrate the requirement of PKCe for Kras-driven lung tumorigenesis in vivo, which is consistent with the impaired transformed growth observed in PKCe-deficient KRAS-dependent NSCLC cells. Moreover,...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
PD-1/PD-L1 blockade is now a well-established therapeutic strategy in non-small cell lung cancer (NSCLC). Pembrolizumab monotherapy is approved by Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese Ministry of Health, Labour and Welfare (MHLW) for first-line treatment in metastatic NSCLC with high PD-L1 expression and lack of a targetable driver mutation [1]. The pembrolizumab companion PD-L1 immunohistochemistry (IHC) uses the antibody 22C3 clone. PD-L1 expression detected as tumor cell membrane staining is semi-quantitatively assessed microscopically.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
HER2 mutations have emerged as oncogenic driver gene mutations in non-small cell lung cancer (NSCLC), which have not been described in detail like other driver gene mutations. Here, 295 patients with advanced lung adenocarcinoma were retrospectively screened for HER2 mutations using next-generation sequencing (NGS), and the positive cases were validated by Sanger sequencing. We identified five cases with HER2 exon 20 insertions, representing 1.7% of 295 lung adenocarcinomas. Among them, four different subtypes of HER2 exon 20 insertions were identified, including a rare subtype G778_S779insCPG never reported before with a ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival. Analysis of circulating tumor DNA (ctDNA) in liquid biopsies using next generation sequencing (NGS) prior to or during treatment hold great promise for disease monitoring and treatment guidance of various cancers including NSCLC. Herein, we report a case of a 21-year-old advanced lung adenocarcinoma patient with a low abundanc...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Congenital pulmonary airway malformations (CPAMs) are abnormalities of the lung arising during development. At our institution the majority of type I infantile CPAMs contain mucinous cell clusters (MCCs). The overlapping histology of MCCs and adult in situ mucinous adenocarcinomas, as well as reports of metastatic mucinous adenocarcinoma arising in CPAMs resected later in childhood raise concerns about the malignant potential of these cells. However, after adequate surgical resection, malignant recurrence has not been reported in infants with CPAMs. Despite benign behavior, MCCs often have histologic features that, in an a...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
In this research, we investigated the frequency of common driving genes in 884 patients with non ‐small cell lung cancer and analyzed their association with clinicopathologic parameters in in eastern China. Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration has unique clinicopathologic characteristics. BackgroundThe status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.MethodsThe status of 10 targeted genes was evaluated by next ‐generation s...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsCDDP and PEM with a short hydration is well tolerated in the outpatient setting with limited toxicity.Key pointsSignificant findings of the studyCDDP plus PEM adjuvant therapy with a short hydration method is well tolerated in the outpatient setting with limited toxicity.What this study addsCDDP plus PEM with a short hydration method has the potential to be one of the options of adjuvant therapy in the future.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Erlotinib is a tyrosine kinase inhibitor commonly used in patients with lung cancer. While cutaneous manifestations may develop after the use of erlotinib, including acneiform eruption, paronychia, and xerosis, erlotinib-related necrolytic migratory erythema (NME)-like skin eruptions have not been reported [1]. Here, we described a rare case of NME-like skin eruption that developed in a patient with lung cancer treated with erlotinib.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to demonstrate whether LINC00324 participates in non-small cell lung cancer (NSCLC) pathogenesis through other molecular mechanism. Relative mRNA, lncRNA, and microRNA levels were analyzed using quantitative real-time-polymerase chain reaction (qRT-PCR). Western blot was used to detect protein level. MTT assay shown proliferation ability and transwell assay shown invasive ability. Luciferase reporter assay illustrated the interaction between RNA molecules. In NSCLC, the high expression of LINC00324 had correlation with the poor prognosis. LINC00324 promoted the proliferation and invasion of NSCLC cells whi...
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Tags: Mol Cell Biochem Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Lung Cancer | Stem Cell Therapy | Stem Cells | Study | Transplants